CDKN2D, cyclin dependent kinase inhibitor 2D, 1032

N. diseases: 110; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010346
Disease: Crohn Disease
Crohn Disease
0.050 Biomarker disease BEFREE Consistently, neutralizing antibodies against IL-12/IL-23 p40 and IL-23 p19 have been successfully used in clinical trials for therapy of Crohn´s disease and pilot studies in ulcerative colitis are ongoing. 30563755 2019
CUI: C0010346
Disease: Crohn Disease
Crohn Disease
0.050 Biomarker disease BEFREE Targeting the specific p19 subunit of IL23 is a promising strategy in CD. 30056776 2018
CUI: C0010346
Disease: Crohn Disease
Crohn Disease
0.050 Biomarker disease BEFREE We aimed to investigate the underlying mechanism of action of risankizumab, a monoclonal antibody targeting the IL-23 p19 subunit, previously reported to induce clinical and endoscopic remission in a randomised phase II study in patients with active Crohn's disease. 30032288 2018
CUI: C0010346
Disease: Crohn Disease
Crohn Disease
0.050 Biomarker disease BEFREE Therefore, selective blockade of interleukin-23 via inhibition of p19 might be a viable therapeutic approach in Crohn's disease. 28411872 2017
CUI: C0010346
Disease: Crohn Disease
Crohn Disease
0.050 Biomarker disease BEFREE The mRNA expression of interleukin-8 (IL-8), induced protein-10, tumour necrosis factor-alpha, IL-23 p19 and IL-12 p40, and Toll-like receptors (TLR) 1 and 2 in the ulcerated mucosa was increased in both intestinal TB and Crohn's disease. 23575333 2013